MetaCap

Upstream Bio Inc. (UPB)

NASDAQ: UPBHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.59-0.41 (-20.50%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

UPB stock chart

Technical analysis

Key statistics

All statistics
Market cap
$87.15M
EPS (TTM)
-$3.01
52-week range
1.56 – 33.68
Day range
1.56 – 2.06
Volume / Avg
1.39M / 1.01M
Beta
—

52-week range

$1.56$33.68

UPB stock today

Upstream Bio (UPB) closed at $1.59 on Nov 20, down 20.50% (-$0.41), versus the S&P 500's 3.70% decline. Shares are 95.3% below their 52-week high of $33.68, set on Jan 14, 2026 and 1.9% above the 52-week low of $1.56, near the bottom of the past year's range. UPB is down 94.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 93.8%.

Upstream Bio has posted a net loss over the last twelve months (EPS of -$3.01), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Upstream Bio

Company profile

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. E. Rand Sutherland M.D., M.P.H.
Headquarters
Waltham, MA
Employees
75
IPO year
2024

Financial highlights

Full financials

In fiscal 2025, Upstream Bio generated $2.9 million in revenue, up 20.4% from fiscal 2024. Upstream Bio reported a net loss of $143.4 million, compared with a loss of $62.8 million a year earlier. Operating margin was -5618.8%.

Upstream Bio annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023
Revenue$2.85M$2.37M$2.38M
Growth+20.42%-0.42%—
Net income$-143.44M$-62.81M$-20.54M
EPS (diluted)$-2.66$-5.58$-12.95

Analyst forecast

Forecast

Consensus (7 analysts)

buy

Avg. price target

$21.40+1245.91%

  • Strong buy 1
  • Buy 4
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $9.00High $40.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$-0.75 vs $-0.67
Surprise
-11.94%

UPB news

All UPB news

Upstream Bio peers

Health Care sector
UPB peer companies
CompanyPrice% ChgMarket capCompare
EQEquillium Inc.1.06-5.36%$87.26Mvs UPB
RTSNRetension Pharmaceuticals Inc.10.51-19.22%$87.57Mvs UPB
CPIXCumberland Pharmaceuticals Inc.5.84-7.30%$87.57Mvs UPB
ANIXAnixa Biosciences Inc.2.44-6.15%$84.82Mvs UPB
NTHINeOnc Technologies Holdings Inc.3.15-9.48%$90.88Mvs UPB
CATXPerspective Therapeutics Inc.0.7538-3.85%$91.03Mvs UPB
OGIOrganigram Global Inc.0.583-7.40%$82.27Mvs UPB
HURATuHURA Biosciences Inc.1.25-8.09%$82.20Mvs UPB

Indexes, lists and sector

Upstream Bio stock FAQ

What is Upstream Bio's stock price today?

UPB last traded at $1.59 as of Nov 20, 4:00 PM EST, down 20.50% on the day. Prices are delayed at least 15 minutes.

Who is Upstream Bio's CEO?

Dr. E. Rand Sutherland M.D., M.P.H. is the chief executive officer of Upstream Bio Inc., which has about 75 employees.

What is the UPB 52-week high?

The 52-week high for UPB is $33.68 and the 52-week low is $1.56. The stock is currently 95.3% below its high.

Compare UPB